gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · CGONHealthcareBiotechnology

CG Oncology, Inc. Common stock (CGON)

$67.71+5.70%
Close Nov 4, 2026 · split-adjusted
Nov 3, 2026$64.06▲ 52.89% in range
Nov 3, 2025Low $37.37 · High $80.68Nov 3, 2026
What changed · written from our data
As of Nov 4, 2026

CG Oncology closed at $67.71 on Nov 4, up 5.70%, 16.1% below its 52-week closing high. Volume of 1.4M shares was 1.58× its 20-day average (above normal).

Split-adjusted performance: +6.4% over one month, -0.4% over six months, +61.6% over one year.

In the quarter ended Jun 30, 2026, revenue was $1.16M, with a net margin of -6832.8%.

Short interest was 8.9M shares at the Oct 15 settlement, down 15.0% from the prior report (12.9% of float, 9.7 days to cover).

Market cap$6.00B88.6M shares
Revenue · quarter$1.2M—
Diluted EPS$-0.90—
P/E · TTM—P/S 963.7×
Net margin-6,832.8%Gross -239.2%
Dividend yieldNone
52-week range37.37 – 80.68−16.1% from high
Volume1.4M1.58× 20-day avg
Volatility · 60d43.2%Annualised
Short % of float12.9%9.7 days to cover
Net cash$1.03BCash $1.03B
Next earnings—Not scheduled
Split-adjusted performance
1W +5.9%1M +6.4%3M −9.5%6M −0.4%YTD +63.1%1Y +61.6%3Y —5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum66
Revenue growth—
Net margin13
Value (low P/E)—
Size88

Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.

Short interest

Details →
Shares short8.9M−15.0% vs prior
Days to cover9.7Settled Oct 15
% of float12.9%
Short vol. 10d74.1%of daily volume

Closest peers by size in Biotechnology

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
CGONCG Oncology$67.71+5.70%−0.4%—−6832.8%—$6.00B
IMVTImmunovant$29.90+2.96%+4.3%———$6.18BCompare
KODKodiak Sciences$98.51−0.38%+114.7%———$6.19BCompare
SRRKScholar Rock Holding$46.09+4.80%−2.2%———$5.61BCompare
CRSPCRISPR Therapeutics AG$51.78+3.57%−6.0%+1325.1%−879.6%—$5.01BCompare
ADPTAdaptive Biotechnologies$26.71+3.53%+85.1%+21.5%−55.6%—$4.26BCompare
RLAYRelay Therapeutics$18.03+3.38%+39.6%−48.3%−23916.3%—$3.95BCompare
IOVAIovance Biotherapeutics$8.70−1.47%+112.7%+65.7%−47.6%—$3.94BCompare
KRYSKrystal Biotech$310.84+1.90%+7.6%+30.2%49.5%40.9$9.20BCompare

News about CG Oncology

All news →
CG Oncology to Present at Upcoming Investor Conferences in SeptemberGlobeNewswire Inc. · Sep 2, 2026▲ PositiveKuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law FirmGlobeNewswire Inc. · Jul 29, 2026▼ NegativeCG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet OncologyGlobeNewswire Inc. · Jul 27, 2026▲ PositiveCG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive PatientsGlobeNewswire Inc. · May 15, 2026▲ Positive

Quick answers

What does CG Oncology do?
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
What is CGON's market cap?
$6B, based on the Nov 4 close of $67.71.
Does CG Oncology pay a dividend?
No regular cash dividend has been paid in the last year.
How much of CGON is sold short?
8.9M shares, 12.9% of float, as of Oct 15, 2026.
What sector is CGON in?
Healthcare, in the Biotechnology industry.

About CG Oncology

CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.

HQ: Dallas, TX142 employeesListed Jan 25, 2024cgoncology.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology